Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like ...